Holen Sie sich die Stockscreener-App
56.93
0.54%
-0.31
Vorhandelsmarkt:
56.46
-0.47
-0.83%
Schlusskurs vom Vortag:
$57.24
Offen:
$57.26
24-Stunden-Volumen:
696.79K
Relative Volume:
0.51
Marktkapitalisierung:
$8.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-766.63M
KGV:
-9.9788
EPS:
-5.7051
Netto-Cashflow:
$-712.55M
1W Leistung:
-4.30%
1M Leistung:
-2.68%
6M Leistung:
+25.73%
1J Leistung:
+61.55%
1-Tages-Spanne:
$56.22
$57.80
1-Wochen-Bereich:
$56.13
$60.75
52-Wochen-Spanne:
$28.09
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
56.93 | 8.22B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Jennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market - Seeking Alpha
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares By Investing.com - Investing.com Canada
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock - MarketBeat
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO Jim Wassil sells 2,250 shares in Rule 10b5-1 trade - Stock Titan
PCVX (PCVX) insider James Wassil files planned sales totaling $566,913.91 - Stock Titan
Vaxcyte Executive Compensation, Directors, and Corporate Governance Overview 2025 - Minichart
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake - Stock Titan
Pictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring the 83% Potential Upside in Vaccine Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte Completes Enrollment for Phase 3 VAX-31 Vaccine Trials - HarianBasis.co
[ARS] Vaxcyte, Inc. SEC Filing - Stock Titan
Vaxcyte (NASDAQ: PCVX) 2026 proxy on directors, auditor and say-on-pay - Stock Titan
Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage - Insider Monkey
5 Best 52-Week High US Stocks to Buy - Insider Monkey
Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily
InvestingPro Fair Value predicted Vaxcyte’s 36% decline By Investing.com - Investing.com South Africa
Vaxcyte, Inc. (PCVX) Investor Outlook: A Deep Dive Into Its 74.82% Upside Potential - DirectorsTalk Interviews
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Insiders At Vaxcyte Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Vaxcyte (PCVX) Stock Insider Selling (Edges Lower) 2026-04-15Large Cap Trends - Cổng thông tin điện tử tỉnh Tây Ninh
PCVX Q4 2025 Earnings: Vaxcyte Inc. Misses EPS Estimates, Reports No RevenueExpert Market Insights - UBND thành phố Hải Phòng
PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vaxcyte (NASDAQ:PCVX) Stock Rating Lowered by Wall Street Zen - MarketBeat
How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily
Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance
What is the target price for Vaxcyte Inc stock2026 Momentum Check & AI Forecasted Entry/Exit Points - baoquankhu1.vn
PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vaxcyte CAO Sells $180,000 in Company Stock - National Today
Vaxcyte CAO Sells $180,000 in Stock - National Today
Insider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells 3,000 Shares of Stock - MarketBeat
Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan
Vaxcyte to Present at Annual Healthcare Conference - National Today
Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus - AD HOC NEWS
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan
Vaxcyte (PCVX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Vaxcyte, Inc. (PCVX) Investor Outlook: An 86.71% Potential Upside Raises Eyebrows - DirectorsTalk Interviews
Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI
PCVX Should I Buy - Intellectia AI
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):